Milan, Italy (June 20, 2024)

Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its nomination as finalist in the Startup of the Year 2023 category of the South Europe Startup Awards (SESA).

Marco Ferroni, CEO and co-founder of MgShell, announced its nomination as finalist in the Founder of the Year 2023 category of the South Europe Startup Awards (SESA).

Every year, the Global Startup Awards source the very best startups, most influential individuals and ecosystem players to find the very best technology companies and the talented entrepreneurs behind them.

About MgShell:

MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.